Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zentiva's EBITDA for the
three
months ended in Mar. 2025 was lei75 Mil. Zentiva's Revenue for the
three
months ended in Mar. 2025 was lei271 Mil. Therefore, Zentiva's EBITDA margin for the quarter that ended in Mar. 2025 was 27.51%.
Zentiva (BSE:SCD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zentiva EBITDA Margin % Related Terms
Zentiva EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zentiva's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:SCD vs ZTS, VTRS, NBIX: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zentiva's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zentiva EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zentiva's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zentiva's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zentiva (BSE:SCD) has a EBITDA Margin % of 27.51% as of Mar. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zentiva and its competitors.
Is Zentiva's EBITDA Margin % too high?
Zentiva's current EBITDA Margin % is 27.51%. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Zentiva's value of 27.51% is 119.4% above this industry median. Overall, Zentiva has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Zentiva's EBITDA Margin % compare to ZTS and VTRS?
Zentiva's EBITDA Margin % of 27.51% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.54. Zentiva's value of 27.51% is 119.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zentiva's current EBITDA Margin % of 27.51% is 119.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zentiva and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zentiva's current EBITDA Margin % is 27.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zentiva stock overvalued right now?
Zentiva (BSE:SCD) has a current EBITDA Margin % of 27.51%. The current EBITDA Margin % is 27.51% and 119.4% above the Drug Manufacturers industry median of 12.54. Zentiva's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zentiva (BSE:SCD), the current EBITDA Margin % is 27.51% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zentiva SA is a Romania-based producer of medicines on the local market. The product portfolio of Zentiva SA includes more than 126 products for human use, such as solids (tablets, capsules, and pellets), generic products, and injectable solutions. The company provides products for therapeutic areas such as Cardiovascular diseases, Anti-inflammatory and pain-relieving medications, urologists, Blood diseases, Gastrointestinal and metabolic disorders, Central nervous system, Medicines against infections, and Diseases of the respiratory system.
10GF Score
Get the complete analysis for BSE:SCD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:SCD has been successfully added to your 
